Alinia and Sutent have been removed from the drug lists because of the introduction of generic therapies.
Prime Therapeutics has made several changes to its Medicare Part D formulary effective. Effective September 1, 2021, Romark Laboratories’ Alinia (nitazoxanide) tablets 500 mg and Alinia for suspension 100 mg/5mL have will no longer be covered by Medicare Part D. The change impacts several of the organization’s formularies, including Ideal Formularies and Value & Essential Formularies. Additionally, some client formularies are affected, including those of Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, and Regence.
Alinia is an anti-parasitic agent that is used to treat the symptoms of diarrhea caused by Cryptosporidium parvum or Giardia lamblia.
In March 2021, Lupin launched a generic version of nitazoxanide tablets.
Prime Therapeutics will also remove Pfizer’s Sutent (sunitinib) capsules, 12.5 mg, 25 mg, 37.5 mg, and 50 mg, from the drug list effective September 15, 2021. The change impacts several of the organization’s formularies, including Ideal Formularies and Value & Essential Formularies. Additionally, some client formularies are affected, including those of Alignment, Asuris, Capital Blue Cross, HCSC, Horizon, and Regence.
Sutent is a chemotherapy used to treat advanced or progressive tumors of the stomach, intestines, esophagus, pancreas, or kidneys.
Prime stated that the reason for this change is that a generic is now available from Sun Pharma.
Prime Therapeutics manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid and serves more than one million Medicare beneficiaries.
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
April 12th 2024Jeffrey Casberg, M.S., R.Ph., a senior vice president of clinical pharmacy at IPD Analytics LLC, a drug intelligence firm that advises payers and pharmaceutical companies, talks about how payers are thinking about weight-loss drugs.
Humira Biosimilars Have a Slow Uptake, Finds Samsung Bioepis Report
April 8th 2024Caps on Medicare Part D cost sharing as a result of the Inflation Reduction Act, could reduce members’ financial incentive for switching to a biosimilar, suggests the newest Samsung Bioepis Quarterly Biosimilar Market Report.